Free Trial

OPKO Health (NASDAQ:OPK) Stock Rating Lowered by StockNews.com

OPKO Health logo with Medical background

StockNews.com cut shares of OPKO Health (NASDAQ:OPK - Free Report) from a hold rating to a sell rating in a research report released on Wednesday morning.

A number of other research firms also recently weighed in on OPK. Piper Sandler reaffirmed an "overweight" rating and issued a $3.00 target price on shares of OPKO Health in a research report on Tuesday, September 17th. Barrington Research reiterated an "outperform" rating and set a $2.25 price objective on shares of OPKO Health in a research report on Friday, November 8th. Finally, HC Wainwright reissued a "buy" rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Wednesday, January 8th.

Check Out Our Latest Research Report on OPK

OPKO Health Trading Down 0.7 %

NASDAQ:OPK traded down $0.01 during mid-day trading on Wednesday, reaching $1.47. 2,671,547 shares of the company's stock traded hands, compared to its average volume of 3,076,149. The company has a 50 day moving average price of $1.54 and a 200-day moving average price of $1.50. The firm has a market capitalization of $1.00 billion, a price-to-earnings ratio of -7.74 and a beta of 1.62. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. OPKO Health has a 12-month low of $0.86 and a 12-month high of $1.76.

Insider Activity at OPKO Health

In related news, CEO Phillip Md Et Al Frost purchased 100,000 shares of the business's stock in a transaction on Thursday, November 14th. The shares were acquired at an average price of $1.62 per share, for a total transaction of $162,000.00. Following the purchase, the chief executive officer now owns 211,612,405 shares of the company's stock, valued at $342,812,096.10. This trade represents a 0.05 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have acquired a total of 1,804,255 shares of company stock valued at $2,764,605 over the last ninety days. 47.26% of the stock is owned by company insiders.

Institutional Trading of OPKO Health

Several large investors have recently added to or reduced their stakes in the company. Rubric Capital Management LP lifted its position in OPKO Health by 9.6% during the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company's stock valued at $72,573,000 after purchasing an additional 4,284,336 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of OPKO Health by 142.5% during the third quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company's stock valued at $2,227,000 after acquiring an additional 876,272 shares during the last quarter. PFG Investments LLC raised its position in shares of OPKO Health by 10.4% in the third quarter. PFG Investments LLC now owns 1,061,090 shares of the biotechnology company's stock valued at $1,581,000 after buying an additional 100,125 shares during the last quarter. Clearline Capital LP purchased a new position in OPKO Health in the 3rd quarter worth approximately $1,083,000. Finally, Barclays PLC lifted its position in OPKO Health by 154.5% during the third quarter. Barclays PLC now owns 543,336 shares of the biotechnology company's stock worth $810,000 after buying an additional 329,870 shares in the last quarter. Hedge funds and other institutional investors own 64.63% of the company's stock.

About OPKO Health

(Get Free Report)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.

See Also

Should You Invest $1,000 in OPKO Health Right Now?

Before you consider OPKO Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OPKO Health wasn't on the list.

While OPKO Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Stock Under Pressure: DeepSeek and the AI Tech War
Nuclear Energy’s Comeback: 7 Stocks to Watch in 2025
Pelosi Bets Big on AI: Her Top 5 Stock Picks

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines